Vinge advises Active Biotech on rights offering

Vinge advises Pricer AB in connection with its issuance of senior unsecured bonds and early redemption

Vinge advises Pricer AB (publ) in connection with its issuance of floating rate senior unsecured bonds of SEK 300 million within a framework of SEK 500 million and early redemption of existing bonds.

Vinge advises Carasent in connection with the listing on Nasdaq Stockholm

Vinge advises Carasent AB (publ) in connection with the listing on Nasdaq Stockholm. The listing is made through a reverse cross-border merger, whereby Carasent AB takes over Carasent ASA, previously listed on Oslo Stock Exchange.

Vinge has advised Apotea in connection with its listing on Nasdaq Stockholm

Vinge has advised Apotea AB (publ) (“Apotea”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on November 26, 2024 and the first day of trading is December 6, 2024.